JOINN (Beijing) & JOINN (Suzhou) Facilities Secure OECD GLP Certification & Re-certification, Mature Quality System Backs Pharma Innovation
2025-11-20
2025.09.15 - 2025.09.22, the two core research facilities under JOINN Laboratories (China) Co., Ltd. — JOINN (Beijing) and JOINN (Suzhou) — completed on-site OECD GLP (Good Laboratory Practice) inspections and re-inspections in sequence. Both facilities recently received official certificates confirming they fully meet OECD GLP standards.

JOINN (Suzhou) first earned OECD GLP certification back in 2015, and has now passed GLP qualification re-inspections six times in a row. For JOINN (Beijing), this marks its debut OECD GLP certification — a milestone that means both of JOINN’s facilities now hold OECD GLP qualifications side by side.
The inspections were led by Poland’s GLP regulatory body. Poland is not only an OECD member, but also a signatory to the OECD Mutual Acceptance of Data (MAD) Agreement and an EU member state. Following Polish, EU, and OECD GLP rules, the inspections fully validated that the quality systems at both JOINN sites are up to code.
For JOINN (Suzhou), the re-inspection zeroed in on maintaining quality system compliance. Inspectors checked the operational status of core modules on-site and traced every step of each research project’s workflow. In the end, they confirmed the facility’s day-to-day operations and management consistently meet GLP requirements.
JOINN (Beijing) underwent a full-scale inspection, covering critical areas like lab facility management, equipment oversight, staff operational standards, raw data integrity, and closed-loop quality assurance controls. The in-depth, detail-focused review proved that JOINN (Beijing)’s quality management system — and how it’s run — fully aligns with OECD GLP rules.
Both facilities passing OECD GLP inspections at the same time reinforces that JOINN’s quality system and quality management practices meet global standards. With its existing China GLP and U.S. FDA GLP qualifications, JOINN is well-positioned to support pharmaceutical innovation worldwide — especially acting as a cornerstone for China’s pharma innovators looking to make their mark on the global stage, by providing reliable safety evaluation support.

